AUPP505798A0 - Novel compound fr225497 substance - Google Patents

Novel compound fr225497 substance

Info

Publication number
AUPP505798A0
AUPP505798A0 AUPP5057A AUPP505798A AUPP505798A0 AU PP505798 A0 AUPP505798 A0 AU PP505798A0 AU PP5057 A AUPP5057 A AU PP5057A AU PP505798 A AUPP505798 A AU PP505798A AU PP505798 A0 AUPP505798 A0 AU PP505798A0
Authority
AU
Australia
Prior art keywords
substance
novel compound
novel
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP5057A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to AUPP5057A priority Critical patent/AUPP505798A0/en
Publication of AUPP505798A0 publication Critical patent/AUPP505798A0/en
Priority to PCT/JP1999/004148 priority patent/WO2000008048A2/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPP5057A 1998-08-04 1998-08-04 Novel compound fr225497 substance Abandoned AUPP505798A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AUPP5057A AUPP505798A0 (en) 1998-08-04 1998-08-04 Novel compound fr225497 substance
PCT/JP1999/004148 WO2000008048A2 (fr) 1998-08-04 1999-08-02 Inhibiteur d'histone déacétylase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP5057A AUPP505798A0 (en) 1998-08-04 1998-08-04 Novel compound fr225497 substance

Publications (1)

Publication Number Publication Date
AUPP505798A0 true AUPP505798A0 (en) 1998-08-27

Family

ID=3809290

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPP5057A Abandoned AUPP505798A0 (en) 1998-08-04 1998-08-04 Novel compound fr225497 substance

Country Status (2)

Country Link
AU (1) AUPP505798A0 (fr)
WO (1) WO2000008048A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348648A1 (en) 1998-10-13 2002-06-03 Fujisawa Pharmaceutical Co Cyclic tetrapeptide compound and use thereof
WO2002055017A2 (fr) * 2000-11-21 2002-07-18 Wake Forest University Methode de traitement de maladies auto-immunes
JP4638148B2 (ja) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US7229963B2 (en) * 2001-10-18 2007-06-12 United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
JP2005517683A (ja) * 2001-12-28 2005-06-16 藤沢薬品工業株式会社 環状テトラペプチド化合物およびその用途
EP1487426B1 (fr) 2002-03-04 2012-08-22 Sloan-kettering Institute For Cancer Research Procedes d'induction de differenciation terminale
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
SE0202157D0 (sv) * 2002-07-09 2002-07-09 Biovitrum Ab Methods for identification of compounds modulating insulin resistance
JPWO2004007758A1 (ja) * 2002-07-12 2005-11-10 アステラス製薬株式会社 血小板減少作用の少ない免疫抑制剤の新規選択方法
CA2504226A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Inhibiteurs d'histone deacetylase destines au traitement de maladies degeneratives de l'oeil
WO2004043352A2 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Inhibiteurs de l'histone desacetylase pour le traitement de maladies et de troubles oculaires, neovasculaires ou oedemateux
EP1582585A4 (fr) * 2002-12-27 2006-06-07 Astellas Pharma Inc Procede de selection d'un nouvel immunosuppresseur
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
KR100924737B1 (ko) 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｄａｃ 억제제를 이용한 암의 치료 방법
CA2535889A1 (fr) 2003-08-29 2005-03-17 Aton Pharma, Inc. Methodes combinees de traitement du cancer
US7935724B2 (en) 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
CA2561617A1 (fr) 2004-04-05 2005-10-20 Aton Pharma, Inc. Promedicaments sous forme d'inhibiteurs d'histones desacetylases
CA2583304A1 (fr) 2005-03-02 2006-09-08 Astellas Pharma Inc. Nouveau marqueur pd pour inhibiteur d'histone deacetylase
CA2615105A1 (fr) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Inhibiteurs de l'histone deacetylase
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP2079462A4 (fr) 2006-09-28 2009-12-02 Merck & Co Inc Compositions pharmaceutiques d'inhibiteurs hdac et composés métalliques chélatables, et complexes métalliques chélatés d'inhibiteurs hdac
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9827212B2 (en) 2009-03-18 2017-11-28 The Trustees Of The University Of Pennsylvania Compositions and methods for treating asthma and other lung diseases
US20120114745A1 (en) * 2009-06-26 2012-05-10 Nam-Mew Pui Method for treating or ameliorating mucocutaneous or ocular toxicities
PL219569B1 (pl) * 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
EP2837681B1 (fr) 2012-04-06 2018-02-21 Kyoto University Méthode d'induction de cellules produisant de l'érythropoïétine
EP3328185B1 (fr) 2015-07-28 2020-06-24 Vilmorin & Cie Procédé pour produire des haploïdes, des dihaploïdes et des plantes haploïdes doublées par culture de microspores isolés
EP3461488A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'une molécule dbait et un inhibiteur de hdac pour le traitement du cancer
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2023041805A1 (fr) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac
WO2023194441A1 (fr) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combinaison d'inhibiteurs de hdac et de statines pour une utilisation dans le traitement du cancer du pancréas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0334991A (ja) * 1989-06-30 1991-02-14 Shionogi & Co Ltd 環状テトラペプチドおよびその製造法
GB2309696B (en) * 1996-01-31 2000-02-23 Merck & Co Inc Antiprotozoal cyclic tetrapeptides
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Also Published As

Publication number Publication date
WO2000008048A3 (fr) 2002-08-15
WO2000008048A2 (fr) 2000-02-17

Similar Documents

Publication Publication Date Title
AUPP505798A0 (en) Novel compound fr225497 substance
AU4580599A (en) Stable no-delivering compounds
AU732211C (en) Novel compound
AU2863899A (en) New compounds
AUPP796798A0 (en) New compound
AU4260199A (en) Novel compounds
AU1424200A (en) Compounds
AU4501699A (en) Aminoazole compounds
AU2014800A (en) Novel compounds
AU5980899A (en) Novel compounds
AU3089199A (en) Preparations containing licariin
AU2350199A (en) Novel aminoorganofunctionalsiloxanes
AU3958899A (en) Photomultiplier
AU1434500A (en) Compounds
AU4814699A (en) Novel compounds
AUPP549998A0 (en) New compound
AU5516599A (en) Substituted 3-aryl-pyrazoles
AU2187799A (en) Novel taxaneterpine compounds
AU4511499A (en) Substituted cyclooctadepsipeptides
AU2863799A (en) New compounds
AU4507899A (en) Substituted n-aryl-o-alkyl-carbamates
AU2725599A (en) Substituted alxoxycarbonyl compounds
AU1649700A (en) Novel formulation
AU2648899A (en) Composition
AUPP506498A0 (en) Novel compound FR225497 substance